New hope for tough colorectal cancer: drug trial uses ultrasound to predict success
NCT ID NCT04355156
First seen Apr 24, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This study tested a drug called axitinib against a placebo in 52 people with advanced colorectal cancer that had spread to the liver and stopped responding to chemotherapy. The goal was to see if axitinib could help patients live longer and to test a new ultrasound method that measures blood flow to tumors to predict who might benefit. The trial is complete, and results will show whether this approach improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.